erlotinib / Generic mfg. - LARVOL DELTA

Xanthoxylin Protects Against Alcoholic Liver Injury via the EGFR/AKT Pathway: A Combined In Silico and In Vitro Study. (PubMed, Molecules) - "Erlotinib, an EGFR inhibitor, reversed the cytoprotective effects of xanthoxylin. Xanthoxylin protects against alcoholic liver injury through regulating the EGFR/AKT pathway, with concurrent modulation of PPARG and PTGS2. These findings provide compelling evidence for xanthoxylin as a promising therapeutic candidate for ALI and establish a foundation for subsequent preclinical development."

IO biomarker • Journal • Preclinical • Hepatology • Liver Failure • BCL2 • CDC37 • ER • HIF1A • HSP90AA1 • PACERR • PARP1 • PPARG • PTGS2

Underutilization Despite Availability: Real-World Radiotherapy Patterns in Lung Cancer in Sub-Saharan Africa (ASTRO 2026) - "Other interventions included primary surgery (17.9%) and systemic therapy (46.2%) with carboplatin (50%), cisplatin (30.6%), and targeted therapy (26.9%) - most commonly Erlotinib (57.1%) and Bevacizumab (38.1%). Despite the increasing availability of modern conformal techniques, radiation therapy utilization for lung cancer in SSA remains overwhelmingly palliative due to the frequency, and extent, of metastatic disease at the time of evaluation. Other findings included limited molecular testing, restricting personalized therapy. Primary lung radiotherapy is increasingly feasible in SSA with investments in infrastructure, capacity building and the advent of conformal radiation therapy."

Clinical • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

A prospective multicenter phase II study of rechallenge treatment with ramucirumab plus erlotinib in patients with EGFR-mutated, advanced non-small cell lung cancer (NJLCG2102) (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study. (ASCO-GU 2025) - P2 | "Although bevacizumab plus erlotinib (Beva/Erlo) showed promising anti-tumor activity, treatment option was limited. Lenvatinib plus tislelizumab combination showed encouraging anti-tumor efficacy and acceptable toxicity profile. The potential of TKI/ICI/ combination to be recommended as the first-line therapy in advanced FH-RCC patient needs further evaluation."

Clinical • IO biomarker • Metastases • P2 data • Genito-urinary Cancer • Oncology • Solid Tumor • FH

Use of receptor and nonreceptor tyrosine kinase inhibitors and Parkinson disease risk. (PubMed, Neurotherapeutics) - "This study investigated associations between Medicare Part D prescription fills prior to PD diagnosis for 7 rTK inhibitors (erlotinib, sorafenib, pazopanib, imatinib, sunitinib, nintedanib, and dasatinib) and 4 nrTK inhibitors (nilotinib, ibrutinib, ruxolitinib, and tofacitinib) and PD risk. Given the chemotherapeutic mechanisms of these medications, and the known cancer-PD inverse relationship, we performed a sensitivity analysis adjusting for relevant cancer subtypes, yielding a similar inverse association. Overall, the use of rTK and nrTK inhibitors was associated with a lower risk of developing PD, although there may be differential impact of this medication class depending on specific inhibition pathways."

Journal • CNS Disorders • Movement Disorders • Oncology • Parkinson's Disease

Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC (clinicaltrials.gov) - P=N/A | N=100 | Recruiting | Sponsor: Tongji Hospital

New trial • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (clinicaltrials.gov) - P=N/A | N=7458 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2026 ➔ Sep 2027 | Trial primary completion date: Sep 2026 ➔ Dec 2025

Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • CTLA4 • PD-1 • PD-L1

Design, synthesis, molecular docking, ADMET and anticancer evaluation of novel pyridine/thiazole hybrids as dual VEGFR-2 and EGFR kinase inhibitors. (PubMed, Bioorg Chem) - "Although it was less effective than sorafenib against the studied cell lines, it was more effective than erlotinib against HepG2, MCF-7, and HCT116, while it was less effective against A549. Similarly, these same compounds displayed superior inhibitory effects on EGFRT790M, with corresponding IC50 values of 0.26, 0.36, 0.44, and 0.50 μM, respectively. Notably, derivatives 5b, 4b, and 4c exhibited good in silico ADMET predictions."

Journal • Oncology • EGFR • KDR

Uracil-Quinazoline Hybrids: Cytotoxicity, Docking, MD, and DFT Studies. (PubMed, Med Chem) - "These findings provide a strong foundation for future optimization and in vivo evaluation of uracil-quinazoline derivatives as targeted cancer therapeutics."

Journal • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Oncology • Solid Tumor • CDK2

NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA). (ASCO 2024) - P3 | "Background: If 5FU/Capecitabine sensitized radiotherapy (RT) is beneficial in the adjuvant (adj) management of PA after adj chemotherapy (chemo) is controversial...Step 1 rndmzd patients (pts) to 5 cycles of gemcitabine +/- Erlotinib...Step 2 eligibility included > 4 cycles chemo (gem, gem combo, (m)FOLFIRINOX)... Chemo+CRT did not improve OS overall, but did improve DFS. Both OS and DFS were improved with Chemo+CRT in node negative pts. Chemo+CRT did not increase Gr 4 or 5 AEs compared to chemo."

Clinical • Gastrointestinal Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • CA 19-9

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis. (PubMed, Cancer Treat Res Commun) - "EU/US subset analysis showed improved efficacy outcomes for RAM + ERL and a safety profile consistent with the overall population. Ramucirumab is a safe and effective addition to standard-of-care EGFR-TKI for EGFR mutation-positive metastatic NSCLC."

Clinical • Journal • Dermatitis • Dermatology • Hypertension • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer. (PubMed, N Engl J Med) - P2 | "The combination of bevacizumab and erlotinib showed antitumor activity in patients with HLRCC-associated or sporadic papillary renal-cell carcinoma. Toxic effects were those known to be associated with this combination. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT01130519.)."

Journal • Cardiovascular • Genetic Disorders • Genito-urinary Cancer • Hypertension • Kidney Cancer • Oncology • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Renal Disease • Solid Tumor • FH

Impact of Posterior Reversible Encephalopathy Syndrome on Hospitalization and Mortality in Tyrosine Kinase Inhibitor-Treated Patients With Hematologic Malignancies: A Real-World Propensity-Matched Analysis (SOHO 2026) - " Using the TriNetX Global Collaborative Network (170 healthcare organizations), we identified TKI-treated patients (imatinib, dasatinib, bosutinib, ibrutinib, or erlotinib) who developed PRES within 1 year of initiation (cohort 1, n = 135) vs TKI-treated controls without PRES (cohort 2, n = 69764), excluding those with cocaine use disorders or hypertensive urgency/emergency. TKI-treated patients, including those receiving CML-directed BCR-ABL1 inhibitors, who developed PRES faced a nearly 2-fold increased hazard of hospitalization (HR, 1.799) and nearly 3-fold increased hazard of death (HR, 2.683) compared to propensity-matched controls, with median survival reduced to 1758 days versus not reached. PRES should be recognized as a high-stakes complication rather than a transient neurological event. Given the markedly shortened time to first hospitalization (190 vs 1404 days), early vigilance for PRES in TKI-treated patients is warranted."

Clinical • Real-world • Real-world evidence • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • BCR

RIT1 Mutated Metastatic Lung Adenocarcinoma - a Case Series (IASLC-WCLC 2026) - "He received Gamma Knife-Stereotactic Radiosurgery (GK-SRS) followed by pembrolizumab, but immune-related toxicities and new brain metastases prompted pembrolizumab discontinuation after six months. He remains alive on maintenance pemetrexed 24 months after diagnosis...She enrolled in the MARIPOSA clinical trial, lazertinib/placebo and osimertinib/placebo...She then commenced Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel (ABCP). Following further pulmonary metastases and progression on docetaxel, she developed cauda equina, necessitating EBRT...She received erlotinib followed by osimertinib...Conclusions : This case series underscores the critical need for comprehensive molecular profiling, as RIT1 mutations may confer resistance across standard LUAD treatments. Prospective studies are required to validate the prognostic/predictive value of clinically relevant mutations in LUAD."

Clinical • IO biomarker • Metastases • Tumor mutational burden • Hepatocellular Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • ARID1A • PIK3CA • RIT1 • TMB

LARGE MALIGNANT TRACHEOESOPHAGEAL FISTULA IN NON-SMALL CELL LUNG CANCER: COMPLICATIONS OF RADIATION AND ERLOTINIB THERAPY (CHEST 2026) - No abstract available

Gastrointestinal Disorder • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase 3 clinical trial of the combination of erlotinib plus ramucirumab compared with osimertinib in untreated advanced or recurrent non-small cell lung cancer with EGFR L858R mutation: The REVOL858R trial (WJOG14420L). (ASCO 2026) - "A planned E+RAM-to-OSI strategy did not improve TFS compared with upfront OSI in EGFR L858R–mutated NSCLC. Safety findings were consistent with known profiles, with higher discontinuation for tolerability in the strategy arm. Trial information: jRCTs051200142."

Clinical • Late-breaking abstract • Metastases • P3 data • Cardiovascular • Hypertension • Interstitial Lung Disease • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pulmonary Disease • Renal Disease • Respiratory Diseases • Solid Tumor • EGFR

A randomized phase II study comparing erlotinib with or without bevacizumab in patients with advanced non–small cell lung cancer (NSCLC) with EGFR mutation. (ASCO 2022) - P2 | "A trend to improvement in PFS was observed with the combination of erlotinib and bevacizumab vs. erlotinib alone in advanced EGFR-mutated NSCLC. Especially, the PFS benefit from this combination was most significant in the pts with BM."

Clinical • P2 data • Dermatology • Lung Cancer • Mucositis • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Stomatitis • EGFR

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. (PubMed, J Clin Oncol) - P1 | "Teliso-V plus erlotinib showed encouraging antitumor activity and acceptable toxicity in EGFR TKI-pretreated patients with EGFR-M+, c-Met+ NSCLC."

Combination therapy • Journal • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

A liposome-in-hydrogel hybrid system for spatially targeted delivery and prolonged intradermal retention of vitamin K1 against EGFR inhibitor-induced skin toxicity. (PubMed, Int J Pharm) - "In an erlotinib-induced skin toxicity model, by restoring EGFR-ERK signaling, VK1-Lipo-Gel more effectively reinforced epidermal barrier function, attenuated inflammatory responses, and ameliorated follicle‑associated alterations. These results demonstrate that optimizing intradermal retention and compartment‑specific distribution, rather than simply increasing transdermal flux, is a superior strategy for managing EGFR inhibitor-induced cutaneous toxicity, and support the translational potential of liposome‑hydrogel hybrids for topical drug delivery."

Journal • Oncology

Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer. (PubMed, J Clin Oncol) - "With erlotinib, a single-nucleotide polymorphism mutation in UBXN11 was associated with significantly worse DFS (P = .01). To our knowledge, this study is the first to demonstrate clinically meaningful OS improvement with adjuvant erlotinib compared with chemotherapy in R0 stage III EGFR+ non-small-cell lung cancer."

Journal • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MUC16 • TP53 • UBXN11

SDRIFE Induced by Erlotinib: First Reported Case (EADV 2026) - No abstract available

Clinical

Identification of multi-target lead compounds from iron-stressed Aspergillus species using LC-MS, in silico analysis, and pharmacokinetics profiling. (PubMed, Nat Prod Res) - "The metabolites exhibited notable binding affinities comparable to standard drugs, including Erlotinib and Rosiglitazone. Pharmacokinetic and toxicity predictions using SwissADME, pkCSM, and ProTox-3.0 indicated favourable drug-likeness, high intestinal absorption, and no predicted hepatotoxicity or immunotoxicity. Overall, these findings suggest that Aspergillus-derived metabolites may serve as promising candidates for future antimicrobial and therapeutic drug discovery studies."

Journal • PK/PD data • Oncology • EGFR

Prognostic Relevance of MTAP Loss in Advanced NSCLC Treated With Targeted Therapies: A Clinicogenomic Analysis (IASLC-WCLC 2026) - "Adenocarcinoma was the predominant histology (75%), and most patients received first-line treatment (66%), primarily with erlotinib (72%)...Similarly, co-alteration subgroup analyses did not show significant associations, including MTAP-EGFRmut (OS HR 2.00, p=0.13; PFS HR 0.59, p=0.20), MTAP-TP53 (OS HR 1.17, p=0.70; PFS HR 0.64, p=0.40), and MTAP-ALK (OS HR 1.55, p=0.7; PFS HR 1.72, p=0.6) Conclusions : MTAP loss was not associated with OS or PFS in this cohort of advanced NSCLC patients treated with targeted therapies. These findings suggest that MTAP loss may reflect the broader genomic context rather than act as an independent prognostic biomarker"

Genomic analysis • Metastases • Omic analysis • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • ALK • CDKN2A • CDKN2B • EGFR • KEAP1 • MTAP • STK11 • TP53

Relay: Final Overall Survival with Erlotinib+Ramucirumab or Placebo in Untreated, EGFR-Mutted Metastatic NSCLC (MNSCLC) (JSMO 2024) - No abstract available

Clinical • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Osimertinib Induced Bone Marrow Aplasia Case Report (IASLC-WCLC 2026) - "Initially, she began treatment with carboplatin and pemetrexed while awaiting next-generation sequencing results...She was treated empirically with cefuroxime due to concurrent respiratory illness within her household...Therapy was switched to erlotinib (Tarceva), and supportive agents including eltrombopag and darbepoetin were initiated...Despite these interventions, her cytopenias persisted, and her blood counts did not recover. Conclusions : This case highlights that osimertinib induced bone marrow aplasia is a rare adverse event but it is important to monitor patients for hematological toxicities closely while on osimertinib therapy."

Case report • Clinical • Anorexia • Aplastic Anemia • Cardiovascular • Cough • Infectious Disease • Interstitial Lung Disease • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor